GRIFOLS

SECOND
HALF
REPORT

2010



THE GROUP'S RECURRENT ACTIVITY, WHICH EXCLUDES RAW MATERIALS, **INCREASED BY +10.7% UP TO 985.9 MILLION EUROS.**

EBITDA FROM RECURRING* **ACTIVITY GREW BY +2.4% TO 272.5 MILLION EUROS**

NET RECURRING PROFIT* **OF 127.7 MILLION EUROS, REPRESENTING 12.9% OF INCOME, DOWN 13.7%** DUE TO INCREASED FINANCIAL EXPENSES

- **In 2010, Grifols met its targets for organic growth, international expansion and investment, and has strengthened its future development through acquisitions such as the proposed purchase of Talecris.**

- **The group's sales have risen by +8.5% to 990.7 million euros**

- **Bioscience grew by +11.3% to 773.4 million euros, driven by growth in the volume of sales of plasma products, primarily in the USA (+23.0%).**

- **Grifols agrees maximum funding of 4,500 million dollars, pending approval by the United States competition authorities (FTC), reflecting the financial markets' confidence in the Talecris acquisition.**

*Excluding the costs associated with the agreement to purchase Talecris Biotherapeutics.

EARNINGS PERFORMANCE IN 2010

Grifols closed the year 2010 with total revenues of 990.7 million euros, an 8.5% increase over 2009. The recurrent activity of the Group, which excludes Raw Materials, increased 10.7% in 2010, with total sales of 985.9 million euros. Sales performed well in all four quarters, and grew at double digit rates, in recurrent terms, in each of the last three quarters.

The impact of the US dollar against the euro was mitigated by Grifols' natural hedge and the geographical diversification of its sales. The overall effect of foreign exchange rates moderately favored total revenues, offsetting the increase in the cost of plasma (the main raw material used by Grifols) and minimizing currency risk.

In this respect, international expansion continued during the year, benefiting sales and contributing to the positive performance of all divisions.

The revenues of the Bioscience division grew 11.3% to 773.4 million euros, with volume as the main growth driver in a context of unfavourable prices. It is worth noting the increase in sales of intravenous immunoglobulin (IVIG) in markets such as Australia and the United States, as well as the strong performance of albumin and factor VIII sales and the gradual penetration of markets such as China, Brazil and Chile, as forecast by the group, in order to grow in line with the expected market increases in each geographical area.

The Diagnostic division grew 5.8%, reporting revenues of 109.1 million euros, 70% of which were generated in international markets. The blood bank, hemostasis and new technologies areas underwent the most significant growth, 17.2%, 18.4% and 9.6% respectively, thereby boosting the division as a whole. The sales of the Hospital division amounted to 89.6 million euros, up 3.7% when compared to 2009. Sales were particularly strong in the last half of the year, due to the rise in sales of Medical Devices (8.4%), Intravenous Therapy (5.5%) and the recovery of the Hospital Logistics area which, despite the budget containment policies prevailing in hospitals in 2010, increased the number of projects awarded during the year.

The cost containment policy was maintained throughout the year, although the higher cost of raw material (plasma) and the minimal contribution of prices towards revenue generation had a direct impact on the gross margin and on EBITDA.

The gross margin was 46.6% over sales, down 210bps. In recurrent terms, excluding transaction costs relating to the proposed acquisition of Talecris, Grifols' EBITDA grew 2.4% to 272.5 million euros, representing 27.5% of sales compared with 29.1% in 2009. Taking into account the transaction costs inherent to the transaction, EBITDA amounts to 255.5 million euros. This represents a 4.0% decrease compared to 2009 EBITDA, and a 25.8% margin over sales.

IN MILLIONS OF EUROS	2010	2009	% VAR.
EBITDA	**255.5**	**266.1**	**-4.0**
% ON SALES	*25.8*	*29.1*	
ADJUSTED EBITDA*	**272.5**	**266.1**	**2.4**
% ON SALES	*27.5*	*29.1*	
NET PROFIT	**115.5**	**148.0**	**-21.9**
% ON SALES	*11.7*	*16.2*	

*Excluding the costs associated with the agreement to purchase Talecris Biotherapeutics.

The finance result increased to 51 million euros in 2010, reducing the group's net profit. This higher increase was due to the funds raised through the issue of bonds in 2009 and an unrealized loss relating to futures contracts with Grifols' shares as the underlying asset. In 2010, excluding transaction costs relating to the proposed purchase of Talecris, net recurrent* profit fell 13.7% to 127.7 million euros, which represents 12.9% of sales. However, if we take into account the transaction costs, the net result reported would total 115.5 million euros, an 11.7% of revenues, and down 21.9% from 2009.

Grifols' net financial debt remained stable in 2010 at approximately 2.4 times EBITDA. At 31 December 2010 net financial debt stood at 604.9 million euros, confirming both a robust balance sheet and the good financial position of the group to meet its future commitments. Working capital management improved during the year, both for receivables and inventories.

In 2010 Grifols obtained credit ratings from Standard & Poor's and Moody's, increasing its transparency and facilitating its access to financial and capital markets. The initial rating assigned to Grifols' senior secured debt by Standard & Poor's is BB, and Ba3 by Moody's.

The forecast investment plan (CAPEX) was upheld during the year. In total, Grifols allocated 95 million euros to the expansion and improvement of its production plants in 2010. The highlights for the Bioscience division were the completion of the new Flebogamma® DIF (IVIG) plant in the United States and the fibrin glue production factory in Spain. In the Diagnostic division investments were made in the Swiss and Australian plants to expand the production of blood-typing cards (MD multicard® and DG Gel® ranges). The main capital investments carried out by the Hospital division related to the start-up of stage III of the production plants in Murcia, and the new paracetamol production line in Barcelona.

*Excluding the costs associated with the agreement to purchase Talecris Biotherapeutics.

INTERNATIONAL EXPANSION

Grifols continued to work towards international expansion in 2010, opening a new representation office in China and new subsidiaries in Colombia and Sweden

International expansion continued to play a critical role in 2010, with 77% of Grifols' yearly sales generated in international markets. The group continued to develop its international diversification, consolidating its sales in areas such as Latin America and the Asia-Pacific region so that, with the United States and Europe, these emerging areas will come to represent a higher percentage of turnover. It is worth noting the growth in Asia and Australia, with sales increasing over 29% and 100%, respectively.

Grifols also continued to strengthen its presence in the United States during 2010. Recurrent sales in this market grew by +22.5% to 338.0 million euros, representing over 34% of the group's total turnover. The European Union was favoured by the contribution of countries such as Italy and the United Kingdom. Sales totalled 432.2 million euros, representing 43.6% of sales and growth of +1.8% in comparison to 2009. Income in Spain represented 23% of total turnover, and remained stable at around 225 million euros up 1% when compared to 2009.

The boost to the international business has been supported by the opening of a representation office in China (Shanghai) and subsidiaries in Colombia (Bogotá) and Sweden (Stockholm). Grifols is currently present in over 90 countries and has its own sales subsidiaries in 23.

SUMMARY OF SALES BY REGION

IN THOUSANDS OF EUROS	2010	% on Sales	2009	% on Sales	% Var	% Var. CC*
EU	432,191	43.6	424,590	46.5	1.8	1.1
US	338,016	34.1	275,991	30.2	22.5	17.9
R.O.W.	215,708	21.8	189,943	20.8	13.6	6.9
SUBTOTAL	985,915	99.5	890,524	97.5	10.7	7.5
RAW MATERIALS	4,815	0.5	22,662	2.5	-78.8	-79.8
TOTAL	990,730	100.0	913,186	100.0	8.5	5.4

*Constant Currency (CC) excludes the impact of exchange rate movements

BREAKDOWN BY DIVISION

All of Grifols' divisions performed positively in 2010, supported by the consolidation of sales in international markets

The Bioscience division generated 78% of Grifols' turnover in 2010, and over 85% of its sales were generated in international markets, with sales increasing particularly in Australia and China. Growth in the U.S. market remained strong and the group progressively gained market share over the course of the year. Plasma derivatives sales in the United States rose by 23% in 2010.

By product, the increase in sales volumes of the principal plasma products was the driver of divisional growth. The leading performers in volume terms were intravenous immunoglobulin (+22.8%), factor VIII (+11.9%) and albumin (+11.4%).

This growth will be boosted in the medium term by new licences being granted. During 2010 the group received authorizations from the FDA (Food & Drug Administration) and the EMA (European Medical Agency) to sell intravenous immunoglobulin (IVIG) at a concentration of 10% in the United States and Europe, making Grifols the first company to have two different concentrations



of liquid IVIG (5% and 10%) on the market in order to better meet the needs of different hospitals and patients. The group also obtained the approval required to sell Flebogamma® DIF at 5% concentration in Chile and antithrombin in Argentina.

With regard to raw material, Grifols continued its resource optimization strategy. In 2010 the volume of plasma collected at plasmapheresis centers in the United States was 2.6 million liters, sufficient to cover the group's requirements and maintain stable levels of inventory.

The Diagnostic division generated 11% of the group's revenues for 2010 and 70% of the division's sales were generated outside Spain. It is worth noting the export of devices to the United States, Europe and China, and the opening of new markets for DG Gel® immunohematology cards. Its production increased thanks to the start of activities in the new Australian plant. In addition to breaking into new markets such as Saudi Arabia, Egypt and Switzerland, sales were consolidated in France, Brazil, Mexico, Turkey, the Czech Republic and China.

The performance of DG Gel® resulted in total reagent production exceeding 13 million units, an increase of over15% in comparison to 2009. At the same time, the Hemostasis area underwent a thorough review, leading to an expansion of its product range in 2010 with the launch of 33 new commercial references.

The division has developed a new automated high processing capacity analyser for blood typing tests, the Erytra®. It was show cased at the XXXI ISBT congress celebrated in Berlin in 2010.

The Hospital division maintained its level of activity, generating approximately 9% of Grifols' total revenues. Most of the sales made by this division are concentrated in the Spanish market, and consequently certain products were affected by the Royal Decree issued in June 2010 regarding additional social security discounts. Additionally, the Hospital Logistics area was impacted by the decrease in hospitals' investments, despite which, sales of this business line grew slightly (+2.6%).

The first BlisPack® system was installed in Portugal, representing Grifols' first step towards the electronic identification of medication in Europe. At a production level the group began manufacturing paracetamol during 2010, while the most significant commercial development was the growth in manufacturing services rendered to third parties, an activity that the group plans to increase to ensure the profitability of its facilities.



The activity of the **Raw Materials and Others division** has progressively declined, as forecast by the group, while other areas of activity, such as that carried out by Grifols Engineering, continue to grow. Grifols Engineering was awarded the construction and integral development of the new installations of the Portuguese pharmaceutical company Bial in Spain, a project with a budget of 10 million euros and a total built area of 5,000 m^2.

Once construction work is completed, the plant is due to come into operation in the fourth quarter of 2011, in line with the original execution and validation schedule. Grifols Engineering's experience in developing biopharmaceutical manufacturing facilities of this sort means that the new Bial plant will benefit from the highest standards of quality and technology.

SUMMARY OF SALES BY DIVISION

IN THOUSANDS OF EUROS	2010	% on Sales	2009	% on Sales	% Var	% Var. CC*
BIOSCIENCE	773,371	78.1	694,969	76.1	11.3	7.7
HOSPITAL	89,552	9.0	86,328	9.4	3.7	2.9
DIAGNOSTIC	109,088	11.0	103,091	11.3	5.8	3.4
RAW MATERIALS AND OTHERS	18,719	1.9	28,798	3.2	-35.0	-35.8
TOTAL	**990,730**	**100.0**	**913,186**	**100.0**	**8.5**	**5.4**

*Constant Currency (CC) excludes the impact of exchange rate movements

2010 CORPORATE OPERATIONS

Grifols anticipates its long-term growth plans via acquisitions and agrees the acquisition of Talecris

On June 7, 2010 Grifols announced it had signed an agreement to purchase the United States company Talecris for an approximate price of 3,400 million dollars (4,000 million dollars including debt) and confirmed its commitment to the long-term growth of the group also via acquisitions.

Under the purchase proposal Grifols will pay 0.641/0.6485* newly issued non-voting shares (Class B) and 19 US dollars in cash for each Talecris share. The funding is already in place. Grifols has a maximum finance of 4,500 million dollars, including two long-term syndicated loans, a senior revolving credit facility and a corporate bond issue. Grifols is on schedule to meet all the conditions to complete the operation, which is still subject to approval by the United States competition authorities (FTC), although it has already been approved by the competition authorities in Spain and Germany among others.

In addition to this operation, in 2010, Grifols purchased 100% of Xepol from Pharmalink; Xepol is a company which manages the intellectual property rights for the treatment of Post-Polio Syndrome (PPS) with intravenous immunoglobulin. The agreement includes patents for the United States, Europe and Japan, and provides Grifols with access to the results obtained in different clinical trials, opening up new therapeutic areas for the company's clinical research projects.

Grifols also purchased 51% of the Spanish-owned biomedicine and biotechnology company, Nanotherapix, with the commitment to promote its development through additional funding in line with the results of research studies currently under way.

*The Share Exchange Equation will depend on the identity of the owner of the Talecris shares at the moment of completion of the Transaction and will be equal to 0.6485 for ordinary holders and 0.641 when the owner is Talecris Holdings, LLC or an administrator and/or director of Talecris. The existence of this exchange equation is the result of an agreement reached on October 29 2010 which brought to a close a Class Action raised by some Talecris shareholders in the state of Delaware against Talecris and Grifols, among others. As a result of the settlement agreement, appraisal rights have been granted to those Talecris shareholders who wish them, and Grifols has agreed to raise the maximum amount of shares to be issued by 500,000 shares, from 86,500,000 to 87,000,000.

PERFORMANCE IN THE FOURTH QUARTER OF 2010

Sales' upward trend continues

Revenues in the fourth quarter were 12.7% higher than in the same period in 2009, totalling 251.9 million euros.

The quarterly results were affected by the increased cost of plasma and by the transaction costs associated with the proposed purchase of Talecris. Quarterly EBITDA taking into account these transaction costs, stood at 53.1 million euros, representing 21.1% as a percent of sales, down 10.2% in comparison to the same quarter of the previous year. Reported net profit for the quarter was 18.5 million euros.

Recurring EBITDA for the quarter, excluding transaction costs, reached 60.4 million euros, representing 24.0% of sales and an increase of 2.1% compared to the fourth quarter of 2009, while net profit stood at 23.4 million euros.

SUMMARY OF SALES BY REGION

IN THOUSANDS OF EUROS	4th Q 2010	% on Sales	4th Q 2009	% on Sales	% Var.	% Var. CC*
EU	109,024	43.3	103,909	46.5	4.9	4.2
US	86,386	34.3	65,088	29.1	32.7	22.0
R.O.W.	55,083	21.8	53,408	23.9	3.1	-5.3
SUBTOTAL	250,493	99.4	222,405	99.5	12.6	7.1
RAW MATERIALS	1,413	0.6	1,189	0.5	18.8	9.9
TOTAL	251,906	100.0	223,594	100.0	12.7	7.2

SUMMARY OF SALES BY DIVISION

IN THOUSANDS OF EUROS	4th Q 2010	% on Sales	4th Q 2009	% on Sales	% Var.	% Var. CC*
BIOSCIENCE	194,615	77.3	170,639	76.3	14.1	7.7
HOSPITAL	24,268	9.6	22,886	10.2	6.0	4.7
DIAGNOSTIC	28,087	11.1	26,848	12.1	4.6	0.8
RAW MATERIALS AND OTHERS	4,936	2.0	3,221	1.4	53.2	49.9
TOTAL	251,906	100.0	223,594	100.0	12.7	7.2

*Constant Currency (CC) excludes the impact of exchange rate movements

2010 HIGHLIGHTS

Grifols has continued to promote technical and safety improvements to its products

Key developments in 2010 included the incorporation of the Mix2Vial® devices for coagulation therapies in the United States, making the reconstitution process of these plasma derivatives easier and safer by enabling needle-free transfer and by adding a holographic seal to the containers holding the plasma derivatives to increase safety levels.

Agreement with Progenika Biopharma to distribute a new blood genotyping test

The distribution agreement entered into with Progenika Biopharma will enable Grifols to distribute the new BLOODchip® blood-group genotyping test internationally. This agreement will also strengthen the Diagnostic division and generate sales estimated at between 50-100 million euros in the next five years.

The FDA approved the Plasma Management System SGP used by Grifols USA for the logistical organization and monitoring of plasma storage

The Plasma Management System is an application designed to manage logistical organization and monitoring of plasma storage. It covers all activities, from the reception of plasma for fractionation, storage and monitoring of plasma units to the preparation of the final consignment.

Grifols expands its agreement with Health Robotics

In addition to distributing the automated I.V. STATION robot, Grifols will also market CytoCare in Spain and Portugal.

The Ministry of Industry in Spain has rated Grifols as excellent

Grifols obtained the highest qualification, excellent, from Plan Profarma 2009, a project which assesses the activity and investment of Spanish companies in R&D+i.

Grifols promotes a new study to treat Alzheimer's disease using plasma products

The study will involve 300 patients receiving combined treatment with therapeutic plasmapheresis and albumin and intravenous immunoglobulin. Grifols has signed an agreement with Fenwall, who will design and build a prototype plasmapheresis machine specifically adapted for the performance of this study.

The FDA and the EMA have authorized the sale of intravenous immunoglobulin at 10% concentration

Grifols has obtained licenses from the FDA and the EMA to start sales of its intravenous immunoglobulin, Flebogamma® DIF, at 10% concentration. This makes Grifols the first company to offer two concentrations of liquid IVIG (5% and 10%).

In June 2010 Grifols held its Ordinary General Shareholders Meeting

The meeting approved distribution of a dividend of 59.18 million euros from 2009 results, representing a payout of 40% of net profit.

CORPORATE SOCIAL RESPONSIBILITY: COMMITMENT TO RESEARCH

In 2010 R&D expenses including the technical area amounted to 40.7 million euros, representing a 14.9% increase compared with the resources allocated in 2009 and 4.1% as a percent of revenues. Grifols has a significant portfolio of R&D projects and the resources necessary to guarantee its research activity in the long term.

It is worth noting the commencement of a new medical study to treat Alzheimer's disease combining therapeutic plasmapheresis with the administration of albumin and IVIG. The study begun in 2011 and will include 300 patients. It is a continuation of the study carried out with another 42 patients in collaboration with two Spanish hospitals and two U.S. hospitals, the preliminary results of which have already been published. Additionally, the approvals obtained from the FDA and EMA to sell 10% Flebogamma® DIF were also the result of the work carried out in the R&D area.

The Diagnostic division finalized the development of a new version of the APTT reagent with synthetic phospholipids, while it continued the developments of a chromogenic kit for PC determination, and a reagent to determine Thrombin Time using liquid human thrombin.

In 2010 a global network of external collaborations was established between Grifols researchers and experts in different medical areas. This network includes collaborations with Spanish universities and research centers, such as the Hospital Clínic, the Hospital Universitario de Salamanca, the Centro Superior de Investigaciones Científicas (CSIC) and the Parc Científic de Barcelona. One of the agreements with the Fundaciò Clínic de Barcelona, will enable Grifols to develop a device to preserve livers for transplant in conditions similar to physiological conditions, instead of at low temperatures, raising the number of livers viable for transplantation. This initiative reflects Grifols' interest in opening up new lines of investigation and complements the Group's current collaborations with the European Consortium for the Study of Chronic Liver Failure, which it leads and finances.

Grifols held a total of 673 patent registrations at the end of 2010, of which 65% related to the Bioscience division. During the year, Grifols obtained 5 new patents for original inventions in Spain, and 12 patent extensions overseas, maintaining its commitment to innovation.

ENVIRONMENTAL MANAGEMENT

In 2010 the group met over 85% of the targets established in the environmental program for 2008-2010, significantly improving its waste management, reducing CO_2 emissions and water consumption and optimizing the quality of the waste produced.

The total waste generated by Grifols' activities in 2010 was reduced by over 15%, and totalled 14,000 t. Additionally, the percentage of recovered compared to eliminated waste has grown substantially, to over 65%.

The main waste produced by the Company is still the polyethylene glycol, associated with the Bioscience division, although in 2010 the group sold almost 5,000 t of this by-product.
This fact, together with the gradual removal of acetone as a solvent in the albumin purification process being implemented at the Los Angeles plasma products plant, has generated savings of over 700,000 euros, with the result that environmental expenditure for the period stood at 2.2 million euros. The main investments in environmental protection in 2010 totalled 2.1 million euros and focused on energy efficiency projects at production plants and offices and on water consumption reduction.

HUMAN RESOURCES

Safeguarding jobs and nurturing the talent of the professionals who work for Grifols are two of the key lines of action in the human resources department. The average accumulated headcount of the group during 2010 was 5,968 employees, in line with the prior year. The number of training hours per employee was increased by 2 hours to a total of 28, with a concomitant rise in the number of courses and participants. The programs range from developing management and business skills in the Spanish and Latin American subsidiaries, to continuing the programs already in place in countries such as the United States.

The Grifols Academy of Plasmapheresis continued to expand its activities during the year. In 2010 it introduced its first online training courses (e-learning), with the aim of complementing in-house training and promoting distance learning for employees working in plasma supply and the manufacture of plasma products. In addition, an agreement was signed with the University of Phoenix (an institution accredited by the Higher Learning Commission in 1978 and recognized by the United States Ministry of Education and the Council on Postsecondary Accreditation) so that students who complete courses at the Grifols Academy can obtain university credits for their studies. The Academy's educational program is currently being evaluated and accredited as part of this process.

Finally, a large part of the efforts undertaken by HR were focused on preserving the health and safety of the Group's employees. The implementation and certification of health and safety management models according to OHSAS was established as a strategic objective for all the Spanish companies, while the Group's subsidiaries were required to adapt and establish systems in line with the corporate system implemented under the OHSAS 18.001:2007 standard. Additionally, after completing the psychosocial risk evaluations in 2010, the Group has initiated specific action plans, which include training, development and communication actions as well as plans to monitor their progress and evaluate their effectiveness once implemented.

PROFIT AND LOSS ACCOUNT

IN THOUSANDS OF EUROS	2010	2009	% Var.
TOTAL REVENUE	990,730	913,186	8.5
COST OF SALES	529,400	468,678	13.0
GROSS PROFIT	**461,330**	**444,508**	3.8
% ON SALES	*46.6%*	*48.7%*	
R&D	40,656	35,387	14.9
SGA	210,991	182,593	15.6
OPERATING EXPENSES	*251,647*	*217,980*	15.4
OPERATING PROFIT	**209,683**	**226,528**	-7.4
% ON SALES	*21.2%*	*24.8%*	
FINANCIAL RESULT	51,020	22,585	125.9
SHARE OF PROFIT OF EQUITY ACCOUNTED INVESTMENTS	879	-51	-
PROFIT BEFORE TAXES	**157,784**	**203,994**	-22.7
% ON SALES	*15.9%*	*22.3%*	
INCOME TAX EXPENSE	42,517	56,424	-24.6
NET PROFIT BEFORE MINORITY INTERESTS	115,267	147,570	-21.9
MINORITY INTERESTS	-246	-402	-38.8
GROUP NET PROFIT	**115,513**	**147,972**	-21.9
% ON SALES	*11.7%*	*16.2%*	
E B I T D A	**255,459**	**266,082**	-4.0
% ON SALES	*25.8%*	*29.1%*	
ADJUSTED E B I T D A	**272,458**	**266,082**	2.4
% ON SALES	*27.5%*	*29.1%*	

CASH FLOW

IN THOUSANDS OF EUROS	2010	2009
NET INCOME	115,513	147,972
DEPRECIATION AND AMORTITZATION	45,776	39,554
NET PROVISION CHARGES AND IMPAIRMENT OF ASSETS	913	53
OTHER ADJUSTMENTS-NET	(64,967)	20,310
CHANGES IN INVENTORIES	(18,306)	(113,104)
CHANGES IN TRADE RECEIVABLES	(10,722)	(20,841)
CHANGES IN TRADE PAYABLES	36,045	14,236
CHANGE IN OPERATING WORKING CAPITAL	7,017	(119,709)
NET CASH FLOW FROM OPERATING ACTIVITIES	**104,252**	**88,180**
CAPEX (PROPERTY.PLANT & EQUIP)	(92,254)	(110,115)
R&D/OTHER INTANGIBLE ASSETS	(8,893)	(8,655)
OTHER CASH INFLOW /(OUTFLOW)	(2,909)	(17,183)
NET CASH FLOW FROM INVESTING ACTIVITIES	**(104,056)**	**(135,953)**
FREE CASH FLOW	196	(47,773)
ISSUE (PURCHASE) OF EQUITY	(1,250)	26,655
ISSUE (REPAYMENT) OF DEBT	(1,066)	344,413
DIVIDENDS	(27,282)	(80,913)
OTHER	323	741
NET CASH FLOW FROM FINANCING ACTIVITIES	**(29,275)**	**290,896**
TOTAL CASH FLOW	(29,079)	243,123
CASH AND CASH EQUIVALENTS AT THE START OF THE YEAR	249,372	6,368
EFFECT OF EXCHANGE RATE CHANGES IN CASH AND CASH EQUIVALENTS	19,356	(119)
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	**239,649**	**249,372**

BALANCE SHEET

IN THOUSANDS OF EUROS	2010	2009
ASSETS		
NON-CURRENT ASSETS	744,900	652,599
FIXED ASSETS	434,131	371,705
GOODWILL AND OTHER INTANGIBLE	267,747	243,385
OTHER NON-CURRENT ASSETS	43,022	37,509
CURRENT ASSETS	1,144,082	1,004,578
INVENTORIES	527,865	484,462
TRADE AND OTHER RECEIVABLES	363,622	262,527
OTHER CURRENT FINANCIAL ASSETS	12,946	8,217
CASH AND CASH EQUIVALENTS	239,649	249,372
TOTAL ASSETS	**1,888,982**	**1,657,177**
EQUITY AND LIABILITIES		
EQUITY	707,390	578,528
CAPITAL	106,532	106,532
RESERVES	525,406	436,705
TREASURY STOCK	(1,927)	(677)
INTERIM DIVIDENDS	0	(31,960)
EARNINGS	115,513	147,972
MINORITY INTERESTS	14,350	12,157
OTHER COMPREHENSIVE INCOME	(52,484)	(92,201)
NON-CURRENT LIABILITIES	758,466	779,606
NON CURRENT FINANCIAL LIABILITIES	675,859	715,738
OTHER NON-CURRENT LIABILITIES	82,607	63,868
CURRENT LIABILITIES	423,126	299,043
CURRENT FINANCIAL LIABILITIES	209,871	126,221
OTHER CURRENT LIABILITIES	213,255	172,822
TOTAL EQUITY AND LIABILITIES	**1,888,982**	**1,657,177**

GRIFOLS' DAILY SHARE PRICE VS IBEX 35

(BASE 100, FROM JANUARY 1 TO DECEMBER 31 2010)

The Group's future results could be affected by events related to its own activity, such as shortages of raw materials for the manufacture of its products, the launch of competitive products or changes in the regulations of markets in which it operates. However, at the date of preparation of this report, Grifols has adopted the measures it considers necessary to offset the possible effects of these events.